Active	Status	Sponsor type	Region	Phase	Filter
8 Active 19 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Miller, Elizabeth
NCT04501939: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax	Active, not recruiting	2	5	US	Cirmtuzumab, Zilovertamab, Venetoclax, VENCLEXTA	University of California, San Diego, Oncternal Therapeutics, Inc	Chronic Lymphocytic Leukemia	07/25	07/25
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer	Terminated	1	122	Europe, Canada, US, RoW	Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317	Novartis Pharmaceuticals	BRAF V600 Colorectal Cancer	09/24	09/24